Jlohr Brain Health
  • Home
  • About Us
  • Brain Health Diagnoses
  • Resources on this Site
    • Overviews: 9 Aspects of this Diagnoses
    • Drug Discount Services
    • With Each Diagnosis:
      • YouTube Video
      • Book from Library or Amazon
      • Support Group or Service
    • Tables for Patients:
      • Possible Special Education
      • Possible Social Security Disability Income
      • School Aid
    • Tables for Patients or Professionals
      • Overview of 9 Aspects of this Diagnosis
      • First Pages of Diagnoses from the Diagnostic and Statistical Manual and the Codes from the ICD-10 for Diagnosis and Compensation
  • Medical & Educational Downloads
  • Contact Us
Select Page

Does Adjuvant Metformin Reduce Olanzapine-Induced Metabolic Adverse Effects in Patients Diagnosed With Schizophrenia

by jlohrconsulting | Sep 26, 2025 | Uncategorized

Neuropsychopharmacol Rep. 2025 Dec;45(4):e70061. doi: 10.1002/npr2.70061. ABSTRACT BACKGROUND: Olanzapine is an atypical antipsychotic used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder. In comparison to conventional...

Adolescent suicide behaviors associate with accelerated reductions in cortical gray matter volume and slower decay of behavioral activation Fun-Seeking scores

by jlohrconsulting | Sep 26, 2025 | Uncategorized

Sci Rep. 2025 Sep 25;15(1):32886. doi: 10.1038/s41598-025-16856-y. ABSTRACT Distinguishing those at risk of making a suicide attempt from those who experience only suicidal ideations remains a significant clinical challenge. Longitudinal studies during early...

Defining suicidality phenotypes for genetic studies: perspectives of the Psychiatric Genomics Consortium Suicide Working Group

by jlohrconsulting | Sep 26, 2025 | Uncategorized

Mol Psychiatry. 2025 Sep 25. doi: 10.1038/s41380-025-03271-y. Online ahead of print. ABSTRACT Suicidality phenotypes, consisting of suicidal ideation (SI), suicide attempt (SA), and suicide death (SD), are all heritable but present unique challenges in genome-wide...

Bei Hypertonie auch Depression im Blick haben

by jlohrconsulting | Sep 26, 2025 | Uncategorized

MMW Fortschr Med. 2025 Oct;167(16):73. doi: 10.1007/s15006-025-5321-9. NO ABSTRACT PMID:40999173 | DOI:10.1007/s15006-025-5321-9

Fueling the future: brain bioenergetics as a driver of neurodevelopment and mental health trajectories

by jlohrconsulting | Sep 26, 2025 | Uncategorized

Neuropsychopharmacology. 2025 Sep 25. doi: 10.1038/s41386-025-02230-z. Online ahead of print. NO ABSTRACT PMID:40999231 | DOI:10.1038/s41386-025-02230-z
« Older Entries
Next Entries »

Recent Posts

  • Dissociative Drug-Induced Anxiety
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)

Recent Comments